Vitamin D in schizophrenia and depression:A clinical review by Lally, John & Gaughran, Fiona
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1192/bja.2019.10
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Lally, J., & Gaughran, F. (2019). Vitamin D in schizophrenia and depression: A clinical review. BJPsych
Advances, 25(4), 240-248. https://doi.org/10.1192/bja.2019.10
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 09. Jul. 2020
! 1!
Vitamin D in schizophrenia and depression: a clinical review 
 
John Lally1-3, Fiona Gaughran1,4 
 
 
1Department of Psychosis Studies, Institute of Psychiatry, Psychology & 
Neuroscience, King’s College London, London, UK 
2Department of Psychiatry, Royal College of Surgeons in Ireland, Beaumont 
Hospital, Dublin, Ireland 
3St Vincent’s Hospital Fairview, Dublin, Ireland 
4 National Psychosis Service, South London and Maudsley NHS Foundation 
Trust, London, United Kingdom 
Dr John Lally, MB MSc MRCPsych,  
Department of Psychosis Studies, Institute of Psychiatry, Psychology and 
Neuroscience (IoPPN), King's College London, London, United Kingdom; 
Department of Psychiatry, Royal College of Surgeons in Ireland, Beaumont 
Hospital, Dublin, Ireland; St Vincent’s Hospital Fairview, Dublin, Ireland 
Email: john.lally@kcl.ac.uk (corresponding author) 
Dr Fiona Gaughran MB, BCh, BAO, FRCPI, FRCP, FRCPsych, MD, 
National Psychosis Service, South London and Maudsley NHS Foundation 
Trust, and Reader, Institute of Psychiatry Psychology and Neuroscience, 
Kings College London, United Kingdom. 
Email: Fiona.p.gaughran@kcl.ac.uk  
 
Corresponding author:  
Dr John Lally 
PO63, Department of Psychosis Studies 
Institute of Psychiatry, Psychology and Neuroscience (IoPPN), 
King’s College London, 
De Crespigny Park 
London SE5 8AF 
Email: john.lally@kcl.ac.uk 
Tel: (0044) (0)203 2286000 
Fax:(0044) (0)203 2284312 
! 2!
 
Word count: 3947 
 
Declaration of interest 
Only 1 author (FG) declares a potential conflict of interest, although not in 
relation to this work. 
The other author (JL) declares no conflict of interest 
FG has received support or honoraria for CME, advisory work and lectures 
from Bristol-Myers Squibb, Janssen, Lundbeck, Otsuka, Roche, and 
Sunovion, and has a family member with professional links to Lilly and GSK, 
including shares. 
FG is in part funded by the National Institute for Health Research’s (NIHR) 
Biomedical Research Centre at South London and Maudsley NHS Foundation 
Trust and King’s College London and the South London Collaboration for 
Leadership in Applied Health Research & Care Funding scheme, and by the 
Maudsley Charity. The views expressed in this publication are those of the 
authors and not necessarily those of the NHS, the NIHR or the Department of 
Health and Social Care. 
 
The other author has no financial relationships with any organisations that 
might have an interest in the submitted work in the previous 3 years; there are 
no other relationships or activities that could appear to have influenced the 
submitted work. 
 
 
 
 
 
 
 
 
! 3!
 
Summary 
Evidence from pre-clinical and clinical studies support a role for vitamin D in 
many mental disorders. In this review, we discuss the role of vitamin D in the 
aetiology and treatment of schizophrenia and depression and their physical 
health comorbidities.  Although observational studies support a potential 
association between vitamin D and schizophrenia and depression, sufficient 
high quality evidence from clinical trials does not yet exist to establish a place 
for vitamin D supplementation in optimising clinical response or promoting 
physical health. Completed randomised controlled trials are needed to provide 
insights into the efficacy and safety of vitamin D in the management of mental 
disorders. 
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Learning objectives: 
After reading this article the reader will: 
Understand the epidemiology of vitamin D deficiency in schizophrenia 
Understand the associations of vitamin D with schizophrenia and depression 
Awareness of how to assess, and consider treatment for vitamin D deficiency  
 
Introduction 
Vitamin D is a secosteroid hormone, recognised as a neuroprotective factor 
with a role to play in brain development (Harms 2008, Eyles 2013). Vitamin D 
promotes neurodevelopment, with a range of actions such as promoting cell 
growth and differentiation, regulation of neurotransmission, 
immunomodulation and with antioxidant and anti-inflammatory effects.  
Vitamin D deficiency has been associated with a range of mental disorders 
including mood disorders, psychotic disorders, autism and cognitive decline.   
 
Vitamin D physiology 
Vitamin D belongs to a group of fat-soluble vitamins. Its primary functions are 
to aid the intestinal absorption of calcium and phosphate, and on bone 
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mineralisation (Holick 2013).  The two main forms of vitamin D are: vitamin D3 
or cholecalciferol, which is formed in the skin after exposure to sunlight and 
ergocalciferol, and vitamin D2, which is obtained by irradiation of plants or 
plant materials or foods.  
Vitamin D levels are influenced by environment and lifestyle. Endogenous 
synthesis following cutaneous exposure to ultraviolet B radiation is the 
primary source (see Figure 1). A smaller proportion is acquired from dietary 
sources. It is not a widely appreciated fact, but nutritional sources of vitamin D 
are relatively limited(Holick 2013). Recently a large meta genome-wide 
association study (GWAS) involving 31 studies with a total of 79,366 
individuals identified genetic variants at three loci (group component (GC), 
7-dehydrochlesterol reductase (NADSYN1/DHCR7), and 25-hydroxylase 
(CYP2R1)) influencing vitamin D levels(Jiang 2018), though the findings 
were suggestive of a relatively small heritability rate for vitamin D levels 
indicating that modifiable environmental factors are the main determinant of 
vitamin D levels.  
 
INSERT FIGURE 1 
 
UV sunlight stimulation will depend on the season of the year, latitude and 
skin exposure. Vitamin D levels thus vary seasonally, with deficiency more 
common in winter and at higher latitudes, reflecting ambient levels of sunlight 
(Hypponen and Power 2007) as well as in urban settings due to lifestyle 
choices and lower sunlight exposure (Holick 1995). People with more 
pigmented skin need more sunlight to produce vitamin D, so are particularly 
affected by limited sun exposure; lower levels of vitamin D are consistently 
observed in Black and Asian populations (Ford 2006). Older age is associated 
with lower vitamin D levels, with reduced sunlight exposure and decreased 
ability to synthesize vitamin D cutaneously with sunlight exposure contributing 
factors. 
 
Vitamin D deficiency- epidemiology  
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Vitamin D deficiency is a global problem; more than a billion people worldwide 
are believed to have suboptimal levels (Holick and Chen 2008). A recent 
systematic review of 195 studies including 168,000 people from 44 countries 
identified that 37% had mean 25-hydroxyvitamin D (25(OH)D) concentrations 
lower than <50nmol/L (equivalent to <20ng/ml). Additionally, 6.7% had 
25(OH)D levels below 25 nmol/L (equivalent to <10ng/ml)), corresponding to 
vitamin D deficiency, while only 11% had 25(OH)D levels above 75 nmol/L 
(equivalent to >30ng/ml), the level classed as sufficient (Hilger 2014).  
 
Classification of vitamin D status 
Serum levels of the main circulating form of Vitamin D, 25-hydroxyvitamin D 
(25(OH)D), are usually taken as a proxy of vitamin D status(Ross 2011, Holick 
and Chen 2008), as it is a  more stable compound than the physiologically 
active form, 1,25(OH)2D3, with higher serum concentrations and a longer 
half-life (approximately 20 days compared to 7 hours)(Lips 2007).   
 
Controversy remains about what vitamin D levels are optimal or sufficient. The 
definitions of sufficiency above are based on observations relating to 
25(OH)D’s role in calcium homeostasis and optimal calcium absorption. 
Parathyroid hormone (PTH) levels decline with reducing concentrations of 
25(OH)D, although this decline plateaus and reaches a nadir at 25(OH)D 
concentrations of 75-100nmol/L (30-40ng/ml) (Holick 2007) . Intestinal 
calcium absorption is optimal at concentrations >80nmol/L (equivalent to 
32ng/ml) (Holick and Chen 2008).  The definition of vitamin D sufficiency of 
>50nmol/L 25(OH)D, is based on the observation that PTH levels normalise 
with 25(OH)D concentrations of >50nmol/L(Ross 2011), with similar levels are 
required to prevent osteomalacia and to ensure optimal bone function(Ebeling 
2014). 
Likewise, variable definitions of vitamin D deficiency have been used. Most 
commonly, 25(OH)D concentrations of <50nmol/L (20ng/ml)have been taken 
to indicate deficiency, while concentrations of 51-74nmol/L (21-29ng/ml) 
indicate insufficiency(Holick and Chen 2008). A more conservative definition 
of Vitamin D deficiency provided by the International Osteoporosis 
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Foundation, is serum 25(OH)D concentrations <25nmol/L (<10ng/ml) , with 
insufficiency defined as 25-50nmol/L (10-20ng/ml)(Dawson-Hughes 2010).  
The US Institute of Medicine (IOM) recommend that vitamin D levels 
>20ng/ml (>50nmol/L) are recommended to optimise skeletal benefits, based 
on trials in the general population (Ross 2011). Most recently, the Endocrine 
Society clinical guidelines based on studies of people at high risk for vitamin D 
deficiency recommend that a concentration of 25(OH)D > 30ng/ml (> 
75nmol/L) be attained to improve outcomes (Holick 2011).  
 
Vitamin D and depression 
Research exploring the relationship between suboptimal vitamin D and 
depression risk has provided inconsistent findings.  Several narrative reviews, 
assessing the association between low vitamin D and depression suggest an 
inconclusive relationship. 
A systematic review and meta-analysis of observational studies concluded 
that vitamin D levels were inversely associated with the prevalence of 
depression(Anglin 2013). However, the observational nature of the included 
studies precluded drawing conclusions on a causal relationship (Anglin 2013). 
There remains a paucity of longitudinal data investigating the relationship 
between vitamin D and depression. The few existing studies have provided 
inconclusive results. A recent large-scale population based study of 3251 
adults older than 55 investigating long-term associations between vitamin D 
serum levels and depression identified a cross sectional association between 
low vitamin and depression, but found no evidence for a longitudinal 
relationship (Jovanova 2017). The cross sectional relationship might be 
expected, as people who are depressed may be less able to engage in 
outdoor activity and may limit their sun exposure. However, if vitamin D is a 
risk factor for depression, then we would expect to find that vitamin D 
concentrations had a longitudinal association with depression and depressive 
symptoms, which was not found in this study (Jovanova 2017). This replicated 
previous longitudinal data which failed to identify a longitudinal association 
between low vitamin D and depression(Chan 2011, Toffanello 2014), though 
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was contradictory to findings from two other longitudinal studies(May 2010, 
Milaneschi 2010), which identified a relationship between suboptimal vitamin 
D levels and the prospective onset of depression.  
A meta-analysis of RCTs of vitamin D supplementation as a treatment for 
depression identified six RCTs with 1203 participants (72% females) including 
71 depressed patients (five trials included participants at risk of depression 
and one trial included patients with depression). There was no significant 
effect of vitamin D supplementation on depression scores ((standardized 
mean difference = −0.14, 95% confidence interval =−0.41 to 0.13, P =.32; 
odds ratio =0.93, 95% confidence interval =0.54 to 1.59, P = .79)(Li 2014). 
Both these systematic reviews(Anglin 2013, Li 2014) supported the 
conclusion of previous narrative reviews indicating that no clear causal 
relationship between suboptimal vitamin D and depression has been 
identified.  
Vitamin D augmentation in depression-trials 
Only one small randomised double blind trial of vitamin D3 augmentation of a 
specific antidepressant medication in depressive disorder has taken place. 
Over an eight week period there was a significant improvement in depressive 
symptoms in those whose fluoxetine 20mg daily was augmented with 1500IU 
of vitamin D 3 (n=20) compared to placebo (n=20)(Khoraminya 2013). A 
controlled open label trial of antidepressant (any) augmentation with a single 
oral dose of 300,000IU of vitamin D 3 (n=24) showed a significant 
improvement in depressive symptoms over a 4 week period in comparison to 
antidepressant alone use (n=15)(Zanetidou 2011). Over 90% of the included 
cases treated with vitamin D3 augmentation had a 25(OH)D level <75nmol/L 
(<30ng/ml). A later RCT showed efficacy for a single dose of 300,000 IU 
intramuscular vitamin D (n=40) in improving depressive symptoms at 8 weeks 
following a single injection compared to placebo (n=40), an effect not seen 
with the lower 150,000 IU dose (n=40)(Mozaffari-Khosravi 2013).  
An RCT of 78 people aged 60 and older in receipt of treatment for depression, 
identified a non significant change in the mean depression score between 
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those treated with 50,000 IU of vitamin D3 weekly for 8 weeks compared to 
those treated with placebo (although the mean vitamin D level (22.57± 6.2 
ng/ml) in the treatment group may be considered to have been optimal)(Alavi 
2018). An earlier double blind RCT of 50,000 IU vitamin D weekly compared 
with placebo found a non-significant decrease in depressive symptoms over 
an 8 week period (Sepehrmanesh 2016). A double blind RCT of dialysis 
patients with depression did not identify a significant reduction in depressive 
symptoms at following treatment with 50,000 IU vitamin D weekly for 52 
weeks (n=362)(Wang 2016). 
Vitamin D and bipolar depression 
There has been a single RCT of vitamin D3 augmentation in bipolar 
depression, with no significant difference in depression symptom scores 
between those treated with 5000 IU of vitamin D3 daily (n=16) and placebo 
(n=17) after 12 weeks (Marsh 2017). This was despite a significantly higher 
mean increase in vitamin D levels in the augmentation group (9.9 (8.2) ng/ml) 
compared to the placebo group (1.3 ± 4.3 ng/ml). 
The RCTs to date in mood disorders have been limited by small sample sizes, 
heterogeneity of study populations and vitamin D dosing techniques. These 
trials have produced inconsistent findings, which provide at best a mild signal 
for a beneficial effect of vitamin D on mood, but which is far from conclusive.  
 
Vitamin D supplementation and impact on depression symptom scores 
and mental health 
In addition to trials of vitamin D as a therapeutic agent in depression, RCTs 
have investigated the vitamin D as a preventative agent. A few RCTs have 
investigated vitamin D supplementation in improving depressive symptoms or 
depression scale scores, and those that have done so, had inconsistent 
findings; some showing a positive effect(Jorde 2008, Khoraminya 2013), while 
others finding no significant association(Kjaergaard 2012, Yalamanchili and 
Gallagher 2012, Vieth 2004). There was no association with improved 
depression and anxiety symptom scores in a cohort of young healthy adults 
supplemented with 5000 IU of vitamin D3 for 6 weeks compared to 
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placebo(Dean 2011), though there was a low prevalence of vitamin D 
deficiency in the test population. A randomised trial of vitamin D 
supplementation with 800 IU/day in women aged 70 or more did not identify 
any significant improvement in mental health outcomes with vitamin D3 
supplementation, though the study was limited by a low level of depression in 
the study sample and the moderately low dose of vitamin D3 supplementation 
(Dumville 2006).  A randomised trial investigating the effect of low dose (600 
IU) and high dose (4000 IU) vitamin D 3 daily use (total n=82), found 
significant improvements in well being for those treated with high dose 
therapy at 6 months follow up (Vieth 2004) . Other randomised trials have 
found benefits with vitamin D supplementation in seasonal affective disorder 
(n=8 treated with 100,000 IU of vitamin D and n=7 treated with phototherapy) 
(Gloth 1999), and in improving depressive symptom scores in overweight or 
obese patients (BMI> 28kg/m2) treated with 20,000 IU of vitamin D3 twice 
weekly compared to placebo (cases were not vitamin D deficient nor were 
they depressed) (Jorde 2008).  
These studies have not always focused on patients with clinical depression or 
vitamin D deficiency, rather they have involved vitamin D3 supplementation in 
general population samples, thus limiting interpretation of the findings, and 
contributing to inconclusiveness of findings. These studies are further limited 
by being underpowered, with small sample sizes, and heterogeneous study 
populations. 
 
 
 
 
Vitamin D and psychotic disorders 
Vitamin D insufficiency is highly prevalent in people with schizophrenia and 
other psychotic disorders (Suetani 2017). In a cross sectional study of 324 
community based people with established psychosis, 86% had suboptimal 
vitamin D levels (<50ng/ml).  In a systematic review, 63% met criteria for 
Vitamin D deficiency (with the threshold level to define deficiency  ranging 
from 10-40 ng/ml)(Adamson 2017).  
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We identified that vitamin D levels are lower at the first episode of psychosis 
than in matched healthy controls (Crews 2013), and that 80% (n=134) of FEP 
cases have suboptimal vitamin D levels at time of first contact with 
services(Lally 2018).  Lifestyle and physical health factors associated with an 
increased risk of vitamin D insufficiency or deficiency such as smoking, 
increased body mass index, social withdrawal and inactivity resulting in 
deceased sunlight exposure, are all more frequent in people with psychotic 
disorders. 
 
Epidemiological studies have indicated that those born in late winter/early 
spring (Davies 2003), at higher latitudes (Saha 2006) and in urban settings  
have an increased risk of schizophrenia, leading to suggestions that this risk 
may be mediated by vitamin D deficiency. This association is further 
suggested by the increased rate of psychosis in Black African or Black 
Caribbean migrant populations where vitamin D is low.  Cross sectional data 
in FEP and established psychosis has identified lower mean Vitamin D levels 
in those of Black African or Caribbean ethnicity compared to white 
populations(Lally 2018, Lally 2016), though whether this might differentially 
impact on clinical symptoms or symptomatic response to treatment has not 
been investigated. Prenatal vitamin D deficiency has been hypothesised to 
impact on fetal neural development thus increasing the risk of schizophrenia 
(McGrath 1999). This possibility is supported by a Danish longitudinal case-
control study which showed that vitamin D status in neonates was associated 
with the risk of schizophrenia(McGrath 2010) and by a birth cohort study 
demonstrating an increased risk of schizophrenia in Finnish males not given 
vitamin D supplements during the first year of life (McGrath 2004).  
 
Vitamin D3 supplementation in schizophrenia 
The only randomised trial to date in schizophrenia investigating vitamin D3 
augmentation was conducted in a population of clozapine treated patients 
with treatment resistant schizophrenia (all with vitamin D level <30ng/ml). At 8 
weeks, there was no significant difference in psychotic symptoms between 
those treated with 14,000 IU per week of vitamin D3 (n=24) compared to 
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placebo (n=23), though a signal towards improved cognitive performance 
relating to attention and recall was detected (Krivoy 2017).  
Vitamin D and clinical symptoms in FEP  
A major limitation of work so far in FEP is the cross sectional design of most 
studies, limiting any inference of a causal relationship between vitamin D and 
clinical status-it may as easily be that the relationship identified between 
symptoms and low vitamin D, be it in acute psychotic episodes (Yuksel 2014), 
or in FEP (Graham 2015), may be the result of, rather than a cause of 
psychosis or depression. 
 
We recently investigated the longitudinal relationship between vitamin D 
levels at time of first contact with services in FEP and clinical symptoms at 12 
months, identifying a significant association between higher vitamin D levels 
at first contact for psychosis and lower negative symptoms and total psychotic 
symptoms at 12 month follow up(Lally 2018). This is the first longitudinal 
assessment of vitamin D levels and associations with psychotic symptoms. 
Vitamin D is considered to be neuroprotective, and is postulated to have brain 
antioxidant properties, reducing oxidative stress (Wrzosek 2013, Nerhus 
2016, Mitra 2017) by decreasing the production of the oxidant nitric oxide 
(Garcion 2002), and increasing the production of antioxidants such as 
glutathione (Garcion 1996, Wrzosek 2013).  Previous studies have 
hypothesised that unmitigated oxidative stress can contribute to the 
development of negative symptoms through a dysregulation of glutamate-
GABA excitatory-inhibitory responses (Sullivan and O’Donnell 2012, Albayrak 
2013), while higher glutamate levels in the anterior cingulate cortex have been 
associated with increased negative symptoms in First Episode Schizophrenia 
(Egerton 2012).  Vitamin D’s anti-inflammatory properties are supported by 
the finding that vitamin D supplementation can reduce levels of C-reactive 
protein (CRP), a marker of inflammation (Chen 2014). This is mirrored in 
established psychosis In which an inverse relationship between vitamin D and 
CRP levels has been identified (Lally 2016).  
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Vitamin D and physical health in psychotic disorders 
Vitamin D and cardiometabolic risk in psychotic disorders 
Higher vitamin D levels have been associated with improved longer term 
clinical outcomes, with observational studies showing inverse associations of 
circulating 25-hydroxyvitamin D with risks of death due to cardiovascular 
disease and cancer (Chowdhury 2014). However, there is as yet no 
consistent evidence for routine supplementation.  
 
To date, epidemiological evidence concerning the association between 
vitamin D and cardiometabolic risk factors in community dwelling individuals 
with established psychotic illnesses is limited. For the first time in a population 
with established psychosis, we identified that those with the highest levels of 
vitamin D have a lower prevalence of MetS (20.5 %), compared to those in 
the lowest (39.1 %), second (48.3 %) and third quartile (43.1 %) of vitamin D 
(all p < 0.01)(Lally 2016). This was the first large scale study to have identified 
an association between decreased 25(OH)D levels and cardiovascular risk 
factors in psychotic illnesses. Of interest, we identified associations with 
hypertension and low 25(OH)D levels, which may be a causally related 
finding. This is suggested by findings in the general population where low 
25(OH)D levels are associated with a higher risk of incident cardiovascular 
disease and specifically hypertension(Wang 2008). The strongest correlations 
with low 25(OH)D levels were with factors related to high body fat(Lally 2016) 
, which is supported by the findings that those with increased adipose tissue 
stores (in which vitamin D, being fat soluble, is stored) due to obesity, have 
lower circulating levels of vitamin D due to this increased storage 
capacity(Wortsman 2000).  
 
Vitamin D and bone mineral density (BMD) in psychosis 
Osteoporosis is two and half times more common in schizophrenia compared 
to controls, with 52% having low bone mass (Stubbs 2014) and significantly 
reduced bone mineral density at the lumbar spine(Gomez 2016).  
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Only three studies to date have assessed associations between vitamin D and 
bone mineral density in schizophrenia (Rey-Sanchez 2009, Bergemann 2008, 
Hallahan 2008). In the cross sectional study of Hallahan et al, 15 patients with 
chronic schizophrenia, resident in a long stay residential unit, had BMD 
measures recorded by DEXA scan. There were no significant correlations 
between vitamin D levels (mean 23.8nmol/L (SD=8.9) nmol/L and 
BMD(Hallahan 2008). The Rey-Sanchez et al case-control study measured 
BMD using quantitative ultrasound (QUS) in 73 people with schizophrenia 
(males =48), who were all treated with antipsychotics. There was no 
significant correlation between vitamin D levels (mean 25(OH)D level: 
females: 20.4 (SD=26.1) ng/mL (equivalent to 51.0nmol/L); males: 
15.1(12.0)ng/ml (equivalent to 37.8nmol/L)) and phalangeal BMD values; 
though a significant negative correlation between the PTH and lower bone 
mass was identified in males and females (r = 0.347, p < 0.05)(Rey-Sanchez 
2009). In the case control study of Bergemann et al., 72 premenopausal 
women with schizophrenia (mean age 33.8 years (SD=6.5 years, range 20.5–
45.3 years] were matched to 71 age- and sex-matched healthy controls. 
Those with schizophrenia had no significant difference in BMD (T-score) 
compared to controls. Those with schizophrenia had a significantly reduced 
mean 25(OH)D concentration of 16.3 (SD=7.9) ng/ml compared to controls 
24.6 (SD=11.5) ng/ml (<0.001), though no significant correlation between 
serum 25(OH)D levels and BMD were reported in the patient 
group(Bergemann 2008). If an individual with schizophrenia has a history of 
fragility fractures, or evidence of reduced bone mineral density or 
osteoporosis, then supplementary calcium and vitamin D should be 
prescribed as in the general population(Aspray 2014), along with any direct 
treatments for osteoporosis where indicated.  
 
Managing vitamin D deficiency in psychotic disorders: do we know 
when to screen and treat? 
Given the variation the definition of vitamin D deficiency, in the UK, Public 
Health England recommend the use of vitamin D supplementation (400 
IU/day) for all in winter/autumn months, with year round supplementation 
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advised for those with darker skin pigmentation. Meanwhile, the National 
Osteoporosis Society has set the following serum 25(OH)D thresholds: “<30 
nmol/l (12ng/ml) is deficient; 30–50 nmol/l (12-20ng/ml) may be inadequate in 
some people; >50 nmol/l (>20ng/ml) is sufficient for almost the whole 
population” (Aspray 2014). What does this mean for the clinical care of people 
with schizophrenia? Should we test all patients for vitamin D deficiency? How 
should we interpret test results and what treatment might be considered? The 
answer is that we do not yet know whether and how to adapt the general 
population advice for use in people with psychosis. 
It is more likely than not that a person with established psychosis will have 
suboptimal vitamin D levels(Lally 2016), and a pragmatic approach is 
reasonable when considering vitamin D testing- as in high risk general 
population groups, a presumptive diagnosis of insufficiency could be made, 
based on risk factors, without the need for (expensive) testing of vitamin D 
levels unless symptomatic(Aspray 2014).  
It is perhaps most appropriate to measure vitamin D levels in summer or 
autumn, where a secular trend towards more optimal vitamin D levels will be 
seen. It is reasonable to consider people with schizophrenia and bipolar 
affective disorder as a high-risk group for suboptimal vitamin D levels. The 
National Osteoporosis Society recommend that such patients, as a minimum, 
should be treated with lifestyle advice and over the counter vitamin D 
supplements at a dose of 400 IU/day (Aspray 2014). If the vitamin D level is 
measured and is < 30nmol/L (<12ng/ml), then consideration for correction 
should be made, with a loading dose of 40,000 IU of colecalciferol given orally 
weekly for 7 weeks and vitamin D levels rechecked at 12 weeks to allow the 
level to plateau. If levels are now sufficient (i.e. >50nmol/L (>20ng/ml), then a 
maintenance dose of oral colecalciferol 800-2000 IU/day should be initiated, 
alongside dietary advice and engagement in outdoor activity. A similar 
maintenance regimen is advised for people with vitamin D insufficiency (30-
50nmol/L (12-20 ng/ml)(Aspray 2014).  
Lifestyle advice should be offered to all patients, and education that the best 
source for vitamin D is sensible levels of sunlight exposure. Spending 10-15 
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minutes in the sunlight on most days of a week, with face and arms exposed, 
will suffice to ensure adequate vitamin D levels(Nowson 2012). 
Discussion 
Vitamin D deficiency is associated with psychotic disorders, and with 
depression, as well as with many other chronic physical conditions. The 
question remains whether vitamin D is a causal factor or a consequence of 
these illnesses. Over 90% of people with established psychosis have 
suboptimal vitamin D levels, but depression rates in psychotic disorders are 
not that high, nor are persisting psychotic symptoms universally 
prevalent(Lally 2017). The observed associations could be due to reverse 
causation, the illness affecting the vitamin D levels, although our recent 
prospective paper, while requiring replication, opens the possibility of a direct 
effect of vitamin D levels on outcomes in early psychosis(Lally 2018) . The 
evidence that vitamin D deficiency in early life may be a risk factor for later 
psychosis is somewhat stronger(Eyles 2018).  It may be the case that vitamin 
D when suboptimal is no longer neuroprotective perhaps due to the loss of its 
antioxidant or anti-inflammatory effects, leaving the person more vulnerable to 
emerging illnesses, such as psychosis or depression. In terms of 
supplementation, randomised trials fail to indicate symptom improvements 
with vitamin D augmentation in schizophrenia and depression. Nevertheless, 
vitamin D testing and supplementation has crept into routine medical practice, 
with the assumption that optimization of vitamin D levels will have longer-term 
benefits for physical health.  However evidence for this is lacking, even in the 
general population (Manson 2019).  
Conclusion 
Vitamin D deficiency has been associated with poorer mental health, 
depression and with psychotic disorders, as well as with chronic physical 
conditions. However, the evidence base establishing vitamin D as a potential 
cause rather than consequence of depression is lacking, with some evidence 
that developmental vitamin D deficiency may be pertinent to psychosis risk.  
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Well-designed clinical trials are needed to further study the relationship 
between repletion of vitamin D stores and clinical outcomes in patients with 
depression and schizophrenia before routine testing and supplementation can 
be recommended. In the meantime, the guidelines for the general population 
should be followed, bearing in mind that the risks of vitamin D deficiency in 
those with psychosis and depression are higher than in the general 
population.  
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